IP Library Granted Patent US 10,870,731
Granted Patent B2
US 10,870,731 · App. 16/246,715 · Granted Dec 22, 2020

Method for end-capping a polysiloxane prepolymer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,870,731
App. No.
16/246,715
Filed
Jan 14, 2019
Granted
Dec 22, 2020
Kind
B2
Art Unit
1765
USPC
528/26
Abstract

A method is disclosed which involves the steps of (a) reacting a polysiloxane prepolymer having reactive functional end groups with a non-free radical polymerizable reactive end-capping agent; and (b) reacting the reaction product of step (a) with a free radical polymerizable reactive end-capping agent.

Claims (29)

1. A method comprising the steps of:

(a) reacting a polysiloxane prepolymer having reactive functional end groups with a non-free radical polymerizable reactive end-capping agent, wherein the non-free radical polymerizable reactive end-capping agent is one of a carbonyl-containing non-free radical polymerizable reactive end-capping agent of the general formula:

wherein R 8 is a non-reactive moiety and C(O)X is a non-free radical polymerizable reactive group, or a chloroformate of the general formula:

wherein R 8 has the aforestated meaning; and

(b) reacting the reaction product of step (a) with a free-radical polymerizable reactive end-capping agent.

2. The method of claim 1 , wherein the polysiloxane prepolymer is of formula I:

wherein each R is an independently reactive functional end group, R 1 to R 6 are independently straight or branched, substituted or unsubstituted C 1 -C 30 alkyl group, a substituted or unsubstituted C 3 -C 30 cycloalkyl group, a substituted or unsubstituted C 4 -C 30 cycloalkylalkyl group, a substituted or unsubstituted C 3 -C 30 cycloalkenyl group, a substituted or unsubstituted C 6 -C 30 aryl group, and a substituted or unsubstituted C 7 -C 30 arylalkyl group, and L is independently a linking group.

3. The method of claim 2 , wherein the reactive functional end group includes the same or different reactive functional end group selected from the group consisting of a hydroxyl-containing reactive functional end group and an amine-containing reactive functional end group.

4. The method of claim 1 , wherein the reactive functional end group is —OH.

5. The method of claim 1 , wherein the reactive functional end group is an amine-containing reactive functional end group of the general formula —NHR 7 wherein R 7 is independently hydrogen, an alkyl group, an aryl group, and a cycloalkyl group.

6. The method of claim 1 , wherein the L linking group is independently a straight or branched alkyl group, cycloalkyl group, an aryl group, an ether or polyether group, and an ester group.

7. The method of Claim 1 , wherein R 8 is selected from the group consisting of C 1 to C 18 alkyl groups, C 3 to C 18 cycloalkyl groups and C 6 to C 18 aryl groups and X is selected from the group consisting of —OH, halogen and —OR 9 wherein R 9 is a substituted or unsubstituted heteroaryl or —C(O)R 8 wherein le has the aforestated meanings.

8. The method of claim 1 , wherein the non-free radical polymerizable reactive end-capping agent is reacted with the polysiloxane prepolymer in an amount ranging from about 3 to about 15 mole % of non-free radical polymerizable reactive end-capping agent per mole of end groups in the polymer.

9. The method of claim 1 , wherein the non-free radical polymerizable reactive end-capping agent is reacted with the polysiloxane prepolymer in an amount ranging from about 1 to about 30 mole % of non-free radical polymerizable reactive end-capping agent per mole of end groups in the polymer.

10. The method of claim 1 , wherein the non-free radical polymerizable reactive end-capping agent is reacted with the polysiloxane prepolymer at a temperature ranging from about 0° C. to about 40° C.

11. The method of claim 1 , wherein the free radical polymerizable reactive end-capping agent is a free radical polymerizable reactive end-capping agent having at least one ethylenically unsaturated reactive end group.

12. The method of claim 1 , wherein the free radical polymerizable reactive end-capping agent is selected from the group consisting of a (meth)acrylate-containing free radical polymerizable reactive end-capping agent, a vinyl-containing free radical polymerizable reactive end-capping agent, an unsaturated acidic-containing free radical polymerizable reactive end-capping agent and a styryl-containing free radical polymerizable reactive end-capping agent.

13. The method of claim 12 , wherein the free radical polymerizable reactive end-capping agent is a (meth)acrylate-containing free radical polymerizable reactive end-capping agent selected from the group consisting of a symmetrical (meth)acrylate-containing acid anhydride free radical polymerizable reactive end-capping agent, a (meth)acrylate-containing acid chloride free radical polymerizable reactive end-capping agent, a (meth)acrylate-containing carboxylic acid free radical polymerizable reactive end-capping agent, a (meth)acrylate-containing carbonyl-containing free radical polymerizable reactive end-capping agent, and a (meth)acrylate-containing isocyanate- containing free radical polymerizable reactive end-capping agent.

14. The method of claim 12 , wherein the free radical polymerizable reactive end-capping agent is a vinyl-containing free radical polymerizable reactive end-capping agent selected from the group consisting of a vinyl isocyanate free radical polymerizable reactive end-capping agent, and a vinyl chloroformate free radical polymerizable reactive end-capping agent.

15. The method of claim 12 , wherein the free radical polymerizable reactive end-capping agent is an unsaturated acidic-containing free radical polymerizable reactive end-capping agent which is maleic anhydride.

16. The method of claim 1 , wherein the free radical polymerizable reactive end-capping agent is reacted with the product of step (a) in an excess amount.

17. The method of claim 1 , wherein the free radical polymerizable reactive end- capping agent is reacted with the product of step (a) at a temperature ranging from about 0° C. to about 40° C.

18. The method of claim 1 , wherein the product of step (b) is further reacted with one or more biomedical-device forming monomers to obtain a biomedical device.

19. The method of claim 18 , wherein the biomedical device is an ophthalmic lens.

20. The method of claim 18 , wherein the biomedical device is a contact lens.

21. The method of claim 18 , wherein the biomedical device is an intraocular lens.

22. The method of claim 1 , wherein the carbonyl-containing non-free radical polymerizable reactive end-capping agent is represented by a structure of the general formula:

wherein R 8 has the aforestated meaning.

23. The method of claim 1 , wherein the reaction of the non-free radical polymerizable reactive end-capping agent with the polysiloxane prepolymer is carried out in the presence of a solvent.

Assignments (12)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (059913/0548) Recorded Aug 14, 2025
From: CITIBANK, N.A., AS RESIGNING AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 072469/0091 →
PATENT SECURITY AGREEMENT Recorded Jul 1, 2025
From: BAUSCH & LOMB INCORPORATED; ALDEN OPTICAL LABORATORIES, INC.; BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 071773/0871 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
PATENT SECURITY AGREEMENT Recorded Oct 4, 2023
From: BAUSCH & LOMB INCORPORATED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 065120/0086 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 059121/0001) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061873/0001 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 048556/0758) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH COMPANIES INC.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0484 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 056811/0814) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061872/0669 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 048715/0432) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061849/0512 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 048715/0406) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061775/0290 →
PATENT SECURITY AGREEMENT Recorded May 10, 2022
From: BAUSCH & LOMB INCORPORATED
To: CITIBANK, N.A. AS COLLATERAL AGENT
Reel/Frame 059913/0548 →